Galderma Group AG
Safety and Effectiveness of Restylane® Kysse for Lip Augmentation in Chinese Subjects
- First Posted Date
- 2022-04-25
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 50
- Registration Number
- NCT05342753
- Locations
- 🇨🇳
Galderma Research Site, Taipei, Taiwan
Study Comparing Treatment With Alluzience vs Reconstituted Toxin
- Conditions
- Interventions
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 150
- Registration Number
- NCT05277337
- Locations
- 🇬🇧
Galderma Research Site 1004, London, United Kingdom
🇬🇧Galderma Research Site 1006, London, United Kingdom
🇩🇪Galderma Research Site 2003, Bochum, Germany
Safety and Effectiveness of GP0112 for Cheek Augmentation and Correction of Midface Contour Deficiencies
- Conditions
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 211
- Registration Number
- NCT05262777
- Locations
- 🇨🇦
Galderma Research Site, Montréal, Quebec, Canada
Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines
- Conditions
- Interventions
- First Posted Date
- 2021-12-07
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 132
- Registration Number
- NCT05146999
- Locations
- 🇺🇸
Galderma Research Site, Spring, Texas, United States
Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines
- First Posted Date
- 2021-12-07
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 25
- Registration Number
- NCT05148000
- Locations
- 🇺🇸
Galderma Research Site, New York, New York, United States
Safety and Effectiveness of GP0112 for Cheek Augmentation and Correction
- Conditions
- Interventions
- First Posted Date
- 2021-10-28
- Last Posted Date
- 2022-08-25
- Lead Sponsor
- Galderma R&D
- Registration Number
- NCT05098457
- Locations
- 🇩🇪
Galderma Research Site, Wuppertal, Germany
AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation
- Conditions
- Interventions
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 123
- Registration Number
- NCT05089708
- Locations
- 🇺🇸
Galderma Investigational Site #9950, Evansville, Indiana, United States
🇺🇸Galderma Investigational Site #8636, Fountain Valley, California, United States
🇺🇸Galderma Investigational Site #9948, Hyattsville, Maryland, United States
Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin
- Conditions
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 250
- Registration Number
- NCT05089357
- Locations
- 🇨🇳
Hangzhou Yanshuyuerong medical cosmetology clinic, Hangzhou, Zhejiang, China
To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus
- Conditions
- Interventions
- First Posted Date
- 2021-10-12
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 258
- Registration Number
- NCT05075408
- Locations
- 🇺🇸
Galderma Investigational Site 9965, Miami, Florida, United States
🇺🇸Galderma Investigational Site7016, Miami, Florida, United States
🇺🇸Galderma Investigational Site 9962, Las Vegas, Nevada, United States
Safety and Effectiveness of Poly-l-lactic Acid (PLLA) for the Improvement in Appearance of Cellulite
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 29
- Registration Number
- NCT05064761
- Locations
- 🇨🇦
Galderma Research Site, Vancouver, British Columbia, Canada